Semaglutide denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Semaglutide as "Not FDA-Approved"

This denial typically arises when UnitedHealthcare believes the specific use being requested — the condition, patient population, or route of administration — falls outside the FDA-approved indications for semaglutide. Semaglutide holds distinct FDA approvals tied to particular branded formulations and indicated conditions; a mismatch between what was prescribed and those approved parameters triggers this denial category.

The denial is appealable. FDA approval status is a factual question anchored to the current prescribing label, and errors in how the plan applied that label are correctable on appeal.

## Federal Appeal Framework

You have layered protections:

• Internal appeal — file within the timeframe on your denial notice (typically 180 days for ERISA plans). The plan must issue a decision within 60 days for non-urgent claims.
• External review (ACA §2719 / ERISA §503) — if your internal appeal is denied, you have the right to an independent external review, generally within approximately four months of the original denial. An expedited external review is available when your condition is urgent or your health is at serious risk.

## Documentation to Gather

• Prescribing label (package insert) — obtain the current FDA-approved label for the exact semaglutide formulation prescribed and identify the indication your prescriber is treating.
• Prescriber letter of medical necessity — your clinician should state the specific FDA-approved indication being treated, referencing the label language directly, and explain how your diagnosis maps to that indication.
• Diagnosis documentation — chart notes confirming your diagnosis using standard diagnostic criteria recognized by the relevant professional guideline organization (e.g., the applicable ADA, AACE, or ACC guideline body).
• Prior-treatment history — a dated record of earlier therapies tried, with outcomes, to demonstrate clinical context.
• The insurer's own medical/coverage policy — download UnitedHealthcare's current published policy for semaglutide and note every stated coverage criterion.

## Criteria-Mapping Structure

Build a side-by-side table in your appeal letter:

| Policy/Label Requirement | Evidence from Your Chart | |---|---| | FDA-approved indication (from label) | [Exact ICD-10 diagnosis + chart date] | | Formulation/route approved | [Exact formulation prescribed] | | Any additional coverage criteria from UHC policy | [Chart fact that satisfies each] |

Address the "not FDA-approved" denial head-on by quoting the label's indication language and then quoting your diagnosis from the chart. If the prescribing clinician is using the drug within an approved indication, state that explicitly and cite the label section.

## Key Argument

If the prescriber is treating an FDA-approved indication with an FDA-approved formulation of semaglutide, the denial is factually incorrect and must be reversed. Request that the plan identify the specific label language it relied on to conclude the use is unapproved, and respond to each point with the prescribing label and your chart.